Dr. Craft joined the faculty at Wake Forest in 2012 as professor of Medicine. Dr. Craft is a founding director of the National Institute on Aging (NIA)-funded Wake Forest Alzheimer’s Disease Research Center. Dr. Craft has served as a member of the Alzheimer’s Association Medical and Scientific Advisory Group, the NIA Board of Scientific Counselors, and the Executive Committee of the Alzheimer’s Clinical Trial Consortium.

Dr. Craft’s research program investigates the role of metabolic disorders in the development of Alzheimer’s disease, through translational studies and innovative clinical trials of pharmacologic and dietary intervention to treat or prevent Alzheimer’s disease. She has received a prestigious Zenith Award from the Alzheimer’s Association and a National Institute of Health MERIT award for research excellence.

She led a groundbreaking multisite trial of intranasal insulin for the treatment of Alzheimer’s disease that was funded by the National Alzheimer’s Project Act. This study is being followed up by Dr. Craft’s newly funded PTC award titled “A Phase IIA Trial of Empagliflozin and Intranasal Insulin for MCI/AD,” which is a phase IIA clinical trial looking at safety, feasibility and dosing of a combination of insulin and metabolism-targeting drugs in individuals with mild cognitive impairment or Alzheimer’s disease.